Found 609 clinical trials
TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL
Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and treated under the same strategy. So the investigators put them together as LGLL. The …
- 0 views
- 19 Feb, 2024
The Anti-inflammatory Effects of Hark ny Medicinal Water
The study aims to provide evidence on the effectiveness of Harkny medicinal water in psoriatic and rheumatoid arthritis patients using subjective and objective methods. It is a cross-over study, so first half of patients will receive medicinal water, the other half will receive tap water treatment, and after 6 months …
- 0 views
- 19 Feb, 2024
Ultrasound Features of Dupuytren's Disease (Micro in DD)
Dupuytren's disease (DD) is a benign and progressive condition that affects the palmar aponeurosis with a very high global incidence. It can result in significant loss of hand function or can inhibit an individual's daily activities or work. Current diagnostics rely on Range Of Motion (ROM) measurements and clinical expertise, …
- 0 views
- 07 May, 2025
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.
- 0 views
- 19 Feb, 2024
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
Significant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In particular, the introduction of prostate-specific membrane antigen (PSMA) -based tracers has significantly influenced diagnostic imaging of prostate. If cancer recurs after surgical removal of the prostate, targeted PSMA PET (positron emission tomography) can …
- 0 views
- 19 Feb, 2024
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions. Natalizumab trough concentrations after a 4-weekly interval are high in the large majority of patients which implies a relative overdose in most patients. …
- 0 views
- 19 Feb, 2024
Accuracy of Non-Invasive Blood Pressure Measurements at the Arm Calf and Finger
The present study was designed to assess, in a population of patients admitted to the intensive care unit and already carrying an indwelling arterial catheter, the ability of combined continuous (ClearSight) and intermittent (automatic cuff) non-invasive monitoring to detect low mean BP (<65mmHg). The intra-arterial measurement will be the reference …
- 0 views
- 19 Feb, 2024
Taiwan "Aerosol Box" Versus UMMC "Intubation Box"
This study compares two intubation boxes, that is the Taiwan "Aerosol Box" versus the UMMC "Intubation Box". The importance of this intubation box has come to light recently in view of the COVID-19 pandemic and the fact that intubation is an aerosol-generating procedure. Risks of the healthcare worker attending to …
- 0 views
- 19 Feb, 2024
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.
- 0 views
- 19 Feb, 2024
The Diabetic Retinopathy Screening Prevention and Control Program
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR.
- 0 views
- 19 Feb, 2024